Storia in 2 fonti

Triplet Could Become a New Standard in Tough-to-Treat CLL

Adding a non-covalent BTK inhibitor improved progression-free survival

Raccontata da

benzinga.com

medpagetoday.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mese fa

Triplet Could Become a New Standard in Tough-to-Treat CLL

Adding a non-covalent BTK inhibitor improved progression-free survival

originale

benzinga.com1 mese fa

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Eli Lilly announces BRUIN CLL-322 success: Jaypirca added to venetoclax and rituximab reduces progression-or-death risk by 45% in relapsed or refractory CLL/SLL. The company plans to seek regulatory label expansion and pursue additional Phase 3 trials, extending therapeutic options for patients with prior BTK-inhibitor exposure.

Leggi questa versione → originale

Timeline cronologica

lunedì 15 giugno 2026·benzinga.com
Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
mercoledì 17 giugno 2026·medpagetoday.com
Triplet Could Become a New Standard in Tough-to-Treat CLL
Adding a non-covalent BTK inhibitor improved progression-free survival